CXCR2 and neoplasm: In parallel, we showed that this antagonist led to a lower vessel density and decreased infiltration of microglia/macrophages with a consecutive tumor volume reduction using an immunocompetent GBM rodent model focusing on the CXCL2/CXCR2 signaling pathway due to lacking the IL8 expression in mice [21].